Article and Video CATEGORIES

Cancer Journey

Search By

Are there Clinically Significant Differences Among Immune Checkpoint Inhibitors Treating Lung Cancer?
Thu, 11/05/2015 - 06:00
GRACE Videos and Articles



Drs. Leora Horn, Ben Solomon, & Jack West consider whether the data suggest that the better tested PD1 and PD-L1 inhibitors have differences in activity or tolerability or are essentially interchangeable.


Download Transcript

[ratingwidget post_id=0]

Please feel free to offer comments and raise questions in our Discussion Forums.



Dr. West:  Here at the World Conference on Lung Cancer, like ASCO, immunotherapy was a really hot topic — not a lot of new data here, but still a lot of on going controversies, and one of them, in fact, a featured question at a symposium that I hosted on current debates, is whether these agents are clearly clinically distinct, or largely interchangeable. Do you have a sense of that based on the data, your own impressions, right now?

Dr. Horn:  So, the response rates seem similar — it’s hard to gauge between agents because they seem to have different cut points, different assays. I think that there are going to be some differences between a PD-1 and the PD-L1 agents, and some of the clinical experience that I’ve had at our institution is that, PD-1 patients, for the most part, who have come off therapy, I’ve had less patients who have progressed at a later point, and I’ve actually treated one patient who came off a PD-L1 inhibitor, after progression, with retreatment with a PD-1 inhibitor, who then responded. So, I think that there is interesting science that we need to sort out between the way these different drugs act, but it may turn out that there are some subtle differences in the efficacy between the PD-L1 versus the PD-1 inhibitors.

Dr. West:  I think these are the kinds of questions we’re wrestling with — for instance, as we get other drugs on the market, will it make sense to treat with a PD-L1 inhibitor after a PD-1 inhibitor, or vice versa, or is there a huge amount of cross-resistance, toxicity differences — pneumonitis really a significant issue with PD-1 but maybe not an issue with PD-L1. What are your thoughts Ben?

Dr. Solomon:  Yeah, I think it’s still early days in terms of resolving those questions. I think most of the data, like Leora was describing, are anecdotal now. At a clinical level, response rates and toxicity are broadly similar across the classes. I think there may be some subtle differences that are emerging — I mean there are different targets, PD-1 is a receptor which is on the surface of lymphocytes, whereas PD-L1 is a ligand, which is expressed on the surface of tumor cells, and the ligand can interact with different receptors, and the receptor can be activated by different ligands. So, it wouldn’t surprise me, over time, whether some differences emerge.

Next Previous link

Previous PostNext Post

Related Content

Mandarin LCVL
王林医生用普通话讨论重要的肺癌信息。这些信息包括靶向治疗、晚期疾病的症状、循环肿瘤 DNA、治疗方案等。我们鼓励您与社区中说普通话的人分享。 Dr. Lin Wang discusses important lung cancer information in Mandarin. This information includes targeted therapy, symptoms of advanced disease, circulating tumor DNA, treatment options, and more. We encourage you to share this with the Mandarin speakers in your community. To watch the complete Playlist visit:…;  
Tell your story!  Apply now for the Clinical Trials Experiences through Storytelling Program
We are excited to launch our third year of this program; tell your story and help us help others! Apply Online Now!     GRACE Patient Perspectives: Clinical Trials Experiences Storytelling Program Overview  
Blood Cancer OncTalk
Blood Cancer OncTalk was a live presentation that brought together top oncologists to discuss emerging concepts and treatment options in blood cancer. The program was chaired by Dr. Aaron Goodman, with the participation of Dr. Mazie Tsang, Hematologist / Oncologist; Dr. Autumn Jeong, Hematologist / Oncologist; Dr. Shaji Kumar, Hematologist / Oncologist; and Dr. Sridevi Rajeeve, Hematologist / Oncologist.

Forum Discussions

Hi Caregiver and welcome to Grace.  I'm sorry that you need to be here and hope we can help.  Osimertinib has better efficacy than gefitinib (including OS and reaching the brain)...

Hi Bob, Welcome to Grace.  I'm sorry about your sil.  Unfortunately, cancer becomes resistant to TKIs like tagrisso.  Sometimes all of the cancer becomes resistant at once and sometimes just parts...

Recent Comments

Hi Tammy,  Welome to Grace. …
By JanineT GRACE … on Tue, 05/16/2023 - 13:44
By Tndiuka10 on Fri, 05/12/2023 - 21:13
Hi Caregiver and welcome to…
By JanineT GRACE … on Fri, 05/12/2023 - 14:20
Hi Bob, Welcome to Grace.  I…
By JanineT GRACE … on Tue, 05/02/2023 - 12:29